Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher F Nicodemus

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Immunotherapy|August 29, 2015
Antibody-based immunotherapy of solid cancers: progress and possibilitiesChristopher F Nicodemus
Expert Opinion on Biological Therapy|July 23, 2004
Using antibodies in tumour immunotherapyBirgit C Schultes, Christopher F Nicodemus
Expert Review of Anticancer Therapy|March 11, 2005
Monoclonal antibody therapy of ovarian cancerChristopher F Nicodemus, Jonathan S Berek
Immunotherapy|July 20, 2010
TLR3 agonists as immunotherapeutic agentsChristopher F Nicodemus, Jonathan S Berek
Expert Opinion on Biological Therapy|February 21, 2007
Role of monoclonal antibodies in tumor-specific immunityChristopher F Nicodemus, L Mary Smith, Birgit C Schultes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerBirgit C Schultes, L Mary Smith, Christopher F Nicodemus
Expert Review of Vaccines|August 12, 2003
Immunomodulation with antibodies: clinical application in ovarian cancer and other malignanciesChristopher F Nicodemus, Birgit C Schultes, Brian L Hamilton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Biologic and immunologic therapies for ovarian cancerJonathan S Berek, Birgit C Schultes, Christopher F Nicodemus
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Christopher F Nicodemus
American Journal of Obstetrics and Gynecology|January 19, 2010
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapyChristopher F Nicodemus, Lin Wang, Julie Lucas, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Immunotherapy|August 29, 2015
Antibody-based immunotherapy of solid cancers: progress and possibilitiesChristopher F Nicodemus
Expert Opinion on Biological Therapy|July 23, 2004
Using antibodies in tumour immunotherapyBirgit C Schultes, Christopher F Nicodemus
Expert Review of Anticancer Therapy|March 11, 2005
Monoclonal antibody therapy of ovarian cancerChristopher F Nicodemus, Jonathan S Berek
Immunotherapy|July 20, 2010
TLR3 agonists as immunotherapeutic agentsChristopher F Nicodemus, Jonathan S Berek
Expert Opinion on Biological Therapy|February 21, 2007
Role of monoclonal antibodies in tumor-specific immunityChristopher F Nicodemus, L Mary Smith, Birgit C Schultes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerBirgit C Schultes, L Mary Smith, Christopher F Nicodemus
Expert Review of Vaccines|August 12, 2003
Immunomodulation with antibodies: clinical application in ovarian cancer and other malignanciesChristopher F Nicodemus, Birgit C Schultes, Brian L Hamilton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Biologic and immunologic therapies for ovarian cancerJonathan S Berek, Birgit C Schultes, Christopher F Nicodemus
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Christopher F Nicodemus
American Journal of Obstetrics and Gynecology|January 19, 2010
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapyChristopher F Nicodemus, Lin Wang, Julie Lucas, et al.
Pageof 3